Patrick Hurban, Ph.D. | June 10, 2019

Validation of Oncomine™ Immuno-Oncology NGS Assays at Q2 Solutions 

Trends, Outcomes and Results
This presentation was given at ThermoFisher's Oncology network meeting in May 2019.

Download the presentation to learn:
  1. How Q2 Solutions leverages the ThermoFisher Oncomine™ Immuno-Oncology next generation sequencing (NGS) assays to support our translational research objectives
  2. Q2 Solutions validation trends, outcomes and results of the Oncomine™ Immuno-Oncology NGS assays 

Related Services:
Microsatellite Instability Assay for Response to Immunotherapy

MSI assay for sensitive detection of 5 mononucleotide repeat markers in tumor FFPE specimens

T-cell Receptor (TCR) Sequencing Assay for Characterization of Adaptive Immune Response

Detects TCRβ and TCRγ clonotypes expressed at the mRNA level

Tumor Mutational Burden (TMB) Assay for Response to Immunotherapy

TMB assay utilizing whole exome sequencing (WES) methodology and proprietary variant analysis compendium

Panel-based tumor mutational burden (TMB) analysis of matched tumor and plasma specimens using Illumina’s TruSight Oncology 500 next-generation sequencing assay

AACR 2019 Scientific Poster

Read More